Skip to content
OpenCapital
Get started

CytomX Therapeutics CTMX Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
——
Arcus Biosciences logo
Arcus BiosciencesRCUS
——

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%—
Debt / equity0×-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's accrued progress collections and price adjustments?
CytomX Therapeutics (CTMX) reported accrued progress collections and price adjustments of $979K in Q1 2026.
How has CytomX Therapeutics's accrued progress collections and price adjustments changed year-over-year?
CytomX Therapeutics's accrued progress collections and price adjustments decreased by 94.0% year-over-year, from $16.21M to $979K.
What is the long-term trend for CytomX Therapeutics's accrued progress collections and price adjustments?
Over 5 years (2020 to 2025), CytomX Therapeutics's accrued progress collections and price adjustments has grown at a -64.4% compound annual growth rate (CAGR), from $276.65M to $1.59M.